Telemark Asset Management LLC Acquires 303,589 Shares of Codexis, Inc. (NASDAQ:CDXS)

Telemark Asset Management LLC boosted its position in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 11.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,000,000 shares of the biotechnology company's stock after purchasing an additional 303,589 shares during the period. Codexis makes up approximately 1.4% of Telemark Asset Management LLC's investment portfolio, making the stock its 23rd biggest holding. Telemark Asset Management LLC owned approximately 3.69% of Codexis worth $14,310,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Barclays PLC raised its stake in Codexis by 51.1% in the third quarter. Barclays PLC now owns 207,628 shares of the biotechnology company's stock worth $640,000 after buying an additional 70,255 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Codexis by 0.7% in the third quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company's stock worth $5,065,000 after acquiring an additional 11,082 shares during the period. State Street Corp raised its position in shares of Codexis by 2.7% in the third quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company's stock worth $4,778,000 after acquiring an additional 41,480 shares during the period. Tallon Kerry Patrick acquired a new position in shares of Codexis during the 4th quarter worth about $2,018,000. Finally, Inspire Investing LLC acquired a new position in shares of Codexis during the 4th quarter worth about $405,000. Institutional investors own 78.54% of the company's stock.

Remove Ads

Codexis Trading Down 8.3 %

Shares of NASDAQ:CDXS traded down $0.23 during trading on Thursday, reaching $2.53. The stock had a trading volume of 697,554 shares, compared to its average volume of 588,098. Codexis, Inc. has a fifty-two week low of $2.47 and a fifty-two week high of $6.08. The business has a fifty day moving average price of $4.21 and a 200-day moving average price of $3.95. The stock has a market cap of $209.58 million, a P/E ratio of -2.91 and a beta of 2.12. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.09). The business had revenue of $21.46 million during the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. As a group, analysts anticipate that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 price objective on shares of Codexis in a research note on Friday, November 22nd.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.